Comparison of a twice daily injection of insulin aspart 50 with insulin aspart 30 in patients with poorly controlled type 2 diabetes

References

• Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310(9):948–959.
   PubMed Web of Science ®Google Scholar
• Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci. 2013;1281:64–91.
   PubMed Web of Science ®Google Scholar
• Yabe D, Seino Y, Fukushima M, Seino S. β cell dysfunction versus insulin resistance in the pathogenesis of type 2 diabetes in East Asians. Curr Diab Rep. 2015;15(6):602.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203.
   PubMed Web of Science ®Google Scholar
• Chinese Diabetes Society. Type 2 diabetes prevention and treatment guidelines. Chin J Diabetes Mellitus. 2018;10(1):4–67.
   Google Scholar
• Kalra S, Plata-Que T, Kumar D, et al. Initiation with once-daily BIAsp 30 results in superior outcome compared to insulin glargine in Asians with type 2 diabetes inadequately controlled by oral anti-diabetic drugs. Diabetes Res Clin Pract. 2010;88(3):282–288.
   PubMed Web of Science ®Google Scholar
• Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs. 2006;66(1):31–49.
   PubMed Web of Science ®Google Scholar
• Cucinotta D, Smirnova O, Christiansen JS, et al. Three different premixed combinations of biphasic insulin aspart – comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes. Diabetes Obes Metab. 2009;11(7):700–708.
   PubMed Web of Science ®Google Scholar
• Zafar MI, Ai X, Shafqat RA, et al. Effectiveness and safety of Humalog Mix 50/50 versus Humalog Mix 75/25 in Chinese patients with type 2 diabetes. Ther Clin Risk Manag. 2015;11:27–32.
   PubMed Web of Science ®Google Scholar
• Chinese Society of Endocrinology. Chinese experts consensus statement on premixed insulin in the clinical practice. Drug Evaluation. 2016;13(9):5–11.
   Google Scholar
• Shimizu H, Monden T, Matsumura M, et al. Effects of twice-daily injections of premixed insulin analog on glycemic control in type 2 diabetic patients. Yonsei Med J. 2010;51(6):845–849.
   PubMed Web of Science ®Google Scholar
• Watada H, Su Q, Li PF, et al. Comparison of insulin lispro mix 25 with insulin lispro mix 50 as an insulin starter in Asian patients with type 2 diabetes: a phase 4, open-label, randomized trial (CLASSIFY study). Diabetes Metab Res Rev. 2017;33(1):e2816.
   Web of Science ®Google Scholar
• Scheen AJ, Schmitt H, Jiang HH, et al. Individualizing treatment of type 2 diabetes by targeting postprandial or fasting hyperglycaemia: response to a basal vs a premixed insulin regimen by HbA1c quartiles and ethnicity. Diabetes Metab. 2015;41(3):216–222.
   PubMed Web of Science ®Google Scholar
• Woerle HJ, Neumann C, Zschau S, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77(2):280–285.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Ishii H. Pre-mixed rapid-acting insulin 50/50 analogue twice daily is useful not only for controlling post-prandial blood glucose, but also for stabilizing the diurnal variation of blood glucose levels: switching from pre-mixed insulin 70/30 or 75/25 to pre-mixed insulin 50/50. J Int Med Res. 2010;38(2):674–680.
   PubMed Web of Science ®Google Scholar
• Heise T, Eckers U, Kanc K, et al. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study. Diabetes Technol Ther. 2008;10(6):479–485.
   PubMed Web of Science ®Google Scholar
• Wolever TM, Giddens JL, Sievenpiper JL. Effect of ethnicity on glycaemic index: a systematic review and meta-analysis. Nutr Diabetes. 2015;5:e170.
   PubMed Web of Science ®Google Scholar
• Jia WP, Pang C, Chen L, et al. Epidemiological characteristics of diabetes mellitus and impaired glucose regulation in a Chinese adult population: the Shanghai Diabetes Studies, a cross-sectional 3-year follow-up study in Shanghai urban communities. Diabetologia. 2007;50(2):286–292.
   PubMed Web of Science ®Google Scholar
• Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362(12):1090–1101.
   PubMed Web of Science ®Google Scholar
• Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet. 1999;354(9179):617–621.
   PubMed Web of Science ®Google Scholar
• Cavalot F, Pagliarino A, Valle M, et al. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study. Diabetes Care. 2011;34(10):2237–2243.
   PubMed Web of Science ®Google Scholar
• Yang W, Weng J. Early therapy for type 2 diabetes in China. Lancet Diabetes Endocrinol. 2014;2(12):992–1002.
   PubMed Web of Science ®Google Scholar
• Buse JB, Wolffenbuttel BH, Herman WH, et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care. 2009;32(6):1007–1013.
   PubMed Web of Science ®Google Scholar
• Giugliano D, Maiorino MI, Bellastella G, et al. Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care. 2011;34(2):510–517.
   PubMed Web of Science ®Google Scholar
• Su Q, Liu C, Zheng H, et al. Comparison of insulin lispro mix 25 with insulin lispro mix 50 as insulin starter in Chinese patients with type 2 diabetes mellitus (CLASSIFY study): subgroup analysis of a phase 4 open-label randomized trial. J Diabetes. 2017;9(6):575–585.
   PubMed Web of Science ®Google Scholar